Triggers and oncologic outcome of salvage radical prostatectomy, salvage radiotherapy and active surveillance after focal therapy of prostate cancer.


Journal

World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716

Informations de publication

Date de publication:
Oct 2021
Historique:
received: 14 02 2021
accepted: 10 04 2021
pubmed: 22 4 2021
medline: 19 2 2022
entrez: 21 4 2021
Statut: ppublish

Résumé

Due to the tissue preserving approach of focal therapy (FT), local cancer relapse can occur. Uncertainty exists regarding triggers and outcome of salvage strategies. Patients with biopsy-proven prostate cancer (PCa) after FT for localized PCa from 2011 to 2020 at eight tertiary referral hospitals in Germany that underwent salvage radical prostatectomy (S-RP), salvage radiotherapy (S-RT) or active surveillance (AS) were reported. Prostate specific antigen (PSA) changes, suspicious lesions on mpMRI and histopathological findings on biopsy were analyzed. A multivariable regression model was created for adverse pathological findings (APF) at S-RP specimen. Kaplan-Meier curves were generated to determine oncological outcomes. A total of 90 men were included. Cancer relapse after FT was detected at a median of 12 months (IQR 9-16). Of 50 men initially under AS 13 received S-RP or S-RT. In total, 44 men underwent S-RP and 13 S-RT. At cancer relapse 17 men (38.6%) in the S-RP group [S-RT n = 4 (30.8%); AS n = 3 (6%)] had ISUP > 2. APF (pT ≥ 3, ISUP ≥ 3, pN + or R1) were observed in 23 men (52.3%). A higher ISUP on biopsy was associated with APF [p = 0.006 (HR 2.32, 97.5% CI 1.35-4.59)] on univariable analysis. Progression-free survival was 80.4% after S-RP and 100% after S-RT at 3 years. Secondary therapy-free survival was 41.7% at 3 years in men undergoing AS. Metastasis-free survival was 80% at 5 years for the whole cohort. With early detection of cancer relapse after FT S-RP and S-RT provide sufficient oncologic control at short to intermediate follow-up. After AS, a high secondary-therapy rate was observed.

Identifiants

pubmed: 33881557
doi: 10.1007/s00345-021-03700-x
pii: 10.1007/s00345-021-03700-x
pmc: PMC8519844
doi:

Substances chimiques

Prostate-Specific Antigen EC 3.4.21.77

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3747-3754

Informations de copyright

© 2021. The Author(s).

Références

BJU Int. 2020 Apr;125(4):525-530
pubmed: 31863617
J Urol. 2019 Oct;202(4):717-724
pubmed: 31042109
Eur Urol. 2010 Oct;58(4):567-73
pubmed: 20598436
Eur Urol Focus. 2021 Sep;7(5):1002-1010
pubmed: 33877047
Eur Urol. 2019 Jul;76(1):27-30
pubmed: 30904357
Eur Urol Focus. 2020 Mar 15;6(2):208-211
pubmed: 31053567
World J Urol. 2019 Mar;37(3):397-407
pubmed: 29948045
Eur Urol. 2018 Jul;74(1):84-91
pubmed: 29373215
Eur Urol Open Sci. 2020 Aug 17;21:1-4
pubmed: 34337460
World J Urol. 2019 Aug;37(8):1517-1534
pubmed: 30710157
J Urol. 2019 Jun;201(6):1134-1143
pubmed: 30730409
Abdom Radiol (NY). 2020 Nov;45(11):3882-3895
pubmed: 32447414
J Urol. 2017 Nov;198(5):1069-1076
pubmed: 28551444
World J Urol. 2021 Apr;39(4):1121-1129
pubmed: 32533247
N Engl J Med. 2020 Mar 5;382(10):917-928
pubmed: 32130814
BJU Int. 2017 Oct;120(4):511-519
pubmed: 28267899
Eur Urol. 2016 Jan;69(1):16-40
pubmed: 26427566

Auteurs

Jost von Hardenberg (J)

Department of Urology and Urosurgery, University Medical Centre Mannheim, Medical Faculty Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany. jost.vonhardenberg@medma.uni-heidelberg.de.

Hannes Cash (H)

Department of Urology, Charité University Medicine Berlin, Berlin, Germany.
PROURO, Berlin, Germany.
Clinic of Urology, Urooncology, Robotic-Assisted and Focal Therapy, Medical Faculty and University Clinics of Magdeburg, Magdeburg, Germany.

Daniel Koch (D)

Department of Urology, Fuerth Hospital, Fuerth, Germany.

Angelika Borkowetz (A)

Department of Urology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.

Johannes Bruendl (J)

Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany.

Sami-Ramzi Leyh-Bannurah (SR)

Department of Urology, Pediatric Urology and Urologic Oncology, Prostate Center Northwest, St. Antonius-Hospital, Gronau, Germany.

Timur H Kuru (TH)

Department of Urology, University Hospital Cologne, University of Cologne, Cologne, Germany.

Karl-Friedrich Kowalewski (KF)

Department of Urology and Urosurgery, University Medical Centre Mannheim, Medical Faculty Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.

Daniel Schindele (D)

Clinic of Urology, Urooncology, Robotic-Assisted and Focal Therapy, Medical Faculty and University Clinics of Magdeburg, Magdeburg, Germany.

Katharina S Mala (KS)

Department of Urology, Charité University Medicine Berlin, Berlin, Germany.

Niklas Westhoff (N)

Department of Urology and Urosurgery, University Medical Centre Mannheim, Medical Faculty Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.

Andreas Blana (A)

Department of Urology, Fuerth Hospital, Fuerth, Germany.

Martin Schostak (M)

Clinic of Urology, Urooncology, Robotic-Assisted and Focal Therapy, Medical Faculty and University Clinics of Magdeburg, Magdeburg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH